UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Sovereign wealth funds: legitimacy, governance, and global power.

1, 2013

Volltextzugriff (PDF)

Is more of a good thing still a good thing? PARP inhibitor retreatment in high-grade ovarian carcinoma

Annals of oncology, 2023-12, Vol.34 (12), p.1074-1076

2023

Volltextzugriff (PDF)

Anti-angiogenic agents in ovarian cancer: past, present, and future

Annals of oncology, 2016-04, Vol.27 Suppl 1 (suppl_1), p.i33-i39

2016

Volltextzugriff (PDF)

Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?

Annals of oncology, 2017-11, Vol.28 (suppl_8), p.viii40-viii45

2017

Volltextzugriff (PDF)

PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?

Annals of oncology, 2017-03, Vol.28 (3), p.443-447

2017

Volltextzugriff (PDF)

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Annals of oncology, 2021-06, Vol.32 (6), p.757-765

2021

Volltextzugriff (PDF)

Bacteriophage applications: where are we now?

Letters in applied microbiology, 2010-10, Vol.51 (4), p.363-369

2010

Volltextzugriff (PDF)

Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option

Annals of oncology, 2019-05, Vol.30 (5), p.721-732

2019

Volltextzugriff (PDF)

Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer

Annals of oncology, 2024-05, Vol.35 (5), p.414-428

2024

Volltextzugriff (PDF)

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Annals of oncology, 2011-01, Vol.22 (1), p.39-48

2011

Volltextzugriff (PDF)

Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study

Annals of oncology, 2016-01, Vol.27 (1), p.114-121

2016

Volltextzugriff (PDF)

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer

Gynecologic oncology, 2019-11, Vol.155 (2), p.186-191

2019

Volltextzugriff (PDF)

Bifacial flexible CIGS thin-film solar cells with nonlinearly graded-bandgap photon-absorbing layers

JPhys Energy, 2024-04, Vol.6 (2), p.25012

2024

Volltextzugriff (PDF)

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)

Gynecologic oncology, 2023-07, Vol.174, p.278-287

2023

Volltextzugriff (PDF)

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study

Annals of oncology, 2015-05, Vol.26 (5), p.914-920

2015

Volltextzugriff (PDF)

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study

Annals of oncology, 2017-05, Vol.28 (5), p.996-1004

2017

Volltextzugriff (PDF)

Overexpression of Candida albicans CDR1, CDR2, or MDR1 Does Not Produce Significant Changes in Echinocandin Susceptibility

Antimicrobial Agents and Chemotherapy, 2006-04, Vol.50 (4), p.1148-1155

2006

Volltextzugriff (PDF)

The scope of financial institutions: in-sourcing, outsourcing and off-shoring

Journal of economic geography, 2013-03, Vol.13 (2), p.279-298

2013

Volltextzugriff (PDF)

Wnt signaling in ovarian tumorigenesis

International journal of gynecological cancer, 2008-09, Vol.18 (5), p.954-962

2008

Volltextzugriff (PDF)

Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease

Annals of oncology, 2013-12, Vol.24 Suppl 10, p.x53-x58

2013

Volltextzugriff (PDF)

Efficiency enhancement of ultrathin CIGS solar cells by optimal bandgap grading. Part III: piecewise-homogeneous grading

Applied optics (2004), 2024-04, Vol.63 (11), p.2831

2024

Volltextzugriff (PDF)

Saving the best treatment for last?

Annals of oncology, 2016-09, Vol.27 (9), p.1656-1658

2016

Volltextzugriff (PDF)

Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone

The Lancet (British edition), 2005-04, Vol.365 (9466), p.1256-1258

2005

Volltextzugriff (PDF)

Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix

Journal of clinical oncology, 2000-04, Vol.18 (8), p.1606-1613

2000

Volltextzugriff (PDF)

Optoelectronic optimization of graded-bandgap thin-film AlGaAs solar cells. Part II: optimal antireflection front-surface texturing

Applied optics (2004), 2023-10, Vol.62 (28), p.7487

2023

Volltextzugriff (PDF)

1 – 25 von 1.741

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.312)
Mit Volltextzugriff
(1.324)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(777)
Life Sciences & Biomedicine
(632)
Humans
(523)
Female
(351)
Biological And Medical Sciences
(236)
Male
(230)
Middle Aged
(203)
Adult
(198)
Medical Sciences
(180)
Aged
(154)
Oncology
(130)
Animals
(108)
Physical Sciences
(99)
Social Sciences
(82)
Obstetrics & Gynecology
(78)
General & Internal Medicine
(72)
Adolescent
(67)
Fundamental And Applied Biological Sciences. Psychology
(64)
Physics
(64)
Medicine, General & Internal
(62)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(640)
Journals@Ovid
(620)
Ingenta.com
(582)
EZB Electronic Journals Library
(575)
Access via ScienceDirect (Elsevier)
(332)
Publisher or Other Site
(302)
Wiley-Blackwell Journals
(268)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(267)
IngentaConnect Journals
(171)
Wiley Online Library
(149)
Access via Oxford University Press
(113)
Ebook Central Perpetual and DDA
(89)
eBooks on EBSCOhost
(86)
SpringerLink Journals - AutoHoldings
(83)
BMJ Journals
(73)
JSTOR
(67)
Access via Taylor & Francis
(55)
SAGE Journals
(51)
Taylor & Francis
(50)
Taylor & Francis Online
(48)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

Sovereign wealth funds: legitimacy, governance, and global power.

Is more of a good thing still a good thing? PARP inhibitor retreatment in high-grade ovarian carcinoma

Anti-angiogenic agents in ovarian cancer: past, present, and future

Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?

PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?

Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Bacteriophage applications: where are we now?

Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option

Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer

Bifacial flexible CIGS thin-film solar cells with nonlinearly graded-bandgap photon-absorbing layers

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO)

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study

Overexpression of Candida albicans CDR1, CDR2, or MDR1 Does Not Produce Significant Changes in Echinocandin Susceptibility

The scope of financial institutions: in-sourcing, outsourcing and off-shoring

Wnt signaling in ovarian tumorigenesis

Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease

Efficiency enhancement of ultrathin CIGS solar cells by optimal bandgap grading. Part III: piecewise-homogeneous grading

Saving the best treatment for last?

Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone

Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix

Optoelectronic optimization of graded-bandgap thin-film AlGaAs solar cells. Part II: optimal antireflection front-surface texturing

Suchergebnisse filtern